Plans afoot to grow complex 3D human tumour microenvironment in the lab
A project is in the pipeline to grow a complex 3D tumour microenvironment in vitro.
A project has been awarded 2.43 million euros for the development of the first complex three-dimensional human 'tumour microenvironment' in the laboratory.
The funding was provided by the European Research Council to Queen Mary, University of London, in an effort to revolutionise the field of cancer cell research through bioengineering methods.
It is hoped that the creation of such tumour microenvironments will replace inadequate techniques where human cancer cells are grown in isolation on plastic surfaces.
Dubbed the CANBUILD project, it might also pave the way for better testing of new drugs that target the human tumour microenvironment.
The multi-disciplinary team involved in the study will make the most of the latest advances in tissue engineering, biomechanics, imaging and stem cell biology in the hopes of engineering a 3D human tumour in which the different cell types of the microenvironment will communicate, evolve and grow in vitro.
"Growing an in vitro model which contains all these types of cells will allow us to watch how the cells communicate and how the tumour grows, teaching us more about what is going on in this complex system and hopefully giving us a model we can test new drugs on," said Professor Fran Balkwill.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance